Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2
In conclusion, for the selected patients in STOPDAPT-2 trial, CYP2C19 LOF alleles had no significant, consistent interaction with the effect of 1-month DAPT relative to 12-month DAPT for clinical outcomes, although the study was overtly underpowered.Trial registrySTOPDAPT-2 ClinicalTrials.gov number, NCT02619760.
Source: Cardiovascular Intervention and Therapeutics - Category: Cardiology Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Chromium | Clopidogrel | Cobalt | Coronary Angioplasty | Genetics | Heart | Percutaneous Coronary Intervention | Plavix | Study